Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

This study tests a new drug called milaberon — given as a first-ever systemic (full-body) treatment — in adults aged 18 to 65 with advanced solid tumors (cancers in organs like lung, breast, colon, etc.) that cannot be surgically removed and have spread to other parts of the body. This early study focuses on safety, the right dosing, and early signs of whether the drug is working against different cancer types. **You may be eligible if...** - You are 18 to 65 years old - You have a confirmed advanced or metastatic solid tumor that cannot be surgically removed - You have not previously received any systemic (full-body) anti-cancer drug treatment for your metastatic cancer - You have at least one measurable tumor on a scan - You are in good health (ECOG 0-1) with expected survival of at least 12 weeks - Your blood counts and organ function meet minimum requirements **You may NOT be eligible if...** - You have received prior systemic treatment for metastatic disease (previous neoadjuvant/adjuvant therapy is allowed if it ended more than 6 months ago) - Your cancer is not measurable on standard scans - You have unresolved significant side effects from prior treatments - You have serious organ dysfunction Talk to your doctor to see if this trial is right for you.